Ascletis Submits IND Application to the U.S. FDA for ASC36_37o FDC, a Potentially First-in-Class Once-Weekly Oral Quadruple Peptide Agonist Targeting Amylin Receptor, GLP-1R, GIPR and GCGR, for the Treatment of Obesityprnewswire·Nov 17, 2026 at 09:12 AM01672-0.34%
Ascletis climbs 7% as oral weight-loss drug shows 10.5% efficacy in monkey studyMarket Movers·Nov 17, 2026 at 01:32 AM01672-0.34%
Ascletis Oral Obesity Drug Combination Shows 10.5% Weight Loss in Monkey StudyPUBT·Nov 16, 2026 at 09:03 AM01672-0.34%
Ascletis Submits FDA IND Application for ASC30_39 Obesity TreatmentPUBT·Nov 11, 2026 at 09:03 AM01672-0.34%
Weekly Recap | ASCLETIS-B -4.31%, ObesityWeek data in focusWeekly Review·Nov 7, 2026 at 05:30 AM01672-0.34%
Ascletis Pharma Files HKEX Next-Day Disclosure Return on Share BuybackPUBT·Nov 6, 2026 at 09:41 AM01672-0.34%
Ascletis Pharma Files HKEX Return Announcing Share Buyback for CancellationPUBT·Nov 5, 2026 at 10:12 AM01672-0.34%